American College of Rheumatology

Elaine Husni, MD, discusses how she goes about choosing which therapy is most appropriate for a patient with psoriatic arthritis.

Daniel Clauw, MD, of the University of Michigan, discusses the impact public perception has had on pain management practices for patients with rheumatic diseases and chronic pain.

Using the largest SLE birth cohort ever established, investigators determined children exposed to non-TNF inhibitors in utero were at a low risk of serious infection.

A 19-year analysis presented at ACR 2019 has found opioid use disorder hospitalizations among some rheumatic diseases have increased more than 30-fold since 1998.

Jeffrey Curtis, MD, discusses the results of a study he led examining the safety of the zoster vaccine in immunocompromised populations, specifically patienta with rheumatic diseases receiving TNF inhibitors.

Patients with lupus were at an increased risk of 30-day all-cause mortality following coronary revascularization when compared to patients with diabetes mellitus and the general population.

A new study presented at ACR 2019 is debunking the notion that use of ultrasound to guide treatment in early rheumatoid arthritis provides added benefit over conventional treatment strategies.

A new study has found use of methotrexate could reduce joint damage progression and facilitate bone remodeling in patients with hand osteoarthritis.

A new study presented at ACR 2019 has found spending on bDMARDs nearly doubled between 2012 and 2016, with post-market drug price changes driving most of the increase.

New 2020 osteoarthritis guidelines, developed by the American College of Rheumatology and the Arthritis Foundation, were previewed during ACR 2019.

American College of Rheumatology officials are offering clinicians an early look at some of the recommendations in the drafted gout guidelines the ACR is set to debut in 2020.

The smaller, incomplete study is looking into both the efficacy and safety of the longtime therapy for patients with RA.

Repository corticotropin injection’s nearly six-decade history as a therapy has been tumultuous, but has most recently resulted in its use as an auto-immune drug.

Speaking ambitiously, determining the right tests and initial therapies for patients with rheumatoid arthritis could become optimized.

New data shows patients with rheumatoid arthritis do not change their current treatment to reach a “treat-to-target” goal for low disease activity.

Patients with severe scleroderma who were treated with hematopoietic stem cell transplantation showed significant improvement in long-term outcomes such as survival and functional status.

New data supports the use of etanercept as a monotherapy, or in combination, for the treatment of psoriatic arthritis.

Patients with rheumatoid arthritis who had inadequate response to previous biologic disease-modifying antirheumatic drugs found greater pain relief when taking 2 mg or 4 mg of baricitinib compared with placebo.

The findings led the team to believe a focus on treatment strategy, rather than disease activity, is more indicative of aortic distensibility improvement.

Data from the SELECT-MONOTHERAPY trial in patients with rheumatoid arthritis show that upadacitinib improved outcomes in pain, physical function, health-related quality of life, and morning stiffness.

Obesity in patients with rheumatoid arthritis has been found to influence the effectiveness of JAKi inhibitor treatments.

Eric M. Ruderman, MD, addresses adverse events and toxicities in patients taking disease-modifying antirheumatic drugs (DMARDs).

Investigators assessed the risk of developing malignancies or serious infections with JAK inhibitors for RA treatment.

Patients with active rheumatoid arthritis who are cs/bDMARD-naïve may see a greater reduction in pain and improvement in physical function on baricitinib monotherapy compared with monotherapy of tocilizumab or adalimumab.

Periods of moderate-to-vigorous intensity walking (instead of non-walking) was associated with less risk of total knee replacement over 5 years in patients who have, or who are at high risk of, osteoarthritis of the knee.

The following medications were decreased most frequently and also associated with the greatest impact in terms of reduction of annual cost: adalimumab, etanercept, and rituximab.

In a study announced at the 2016 American College of Rheumatology Annual Meeting in Washington, DC, lupus patients with less education were also likely to wait longer for referral to a specialist.

“This is a subset of the RA population that we should probably give intensive treatment to," Dr. Harrold says of RA patients diagnosed with certain prognosis factors. "Not only clinical adverse sequelae, but also in their social environment, like being able to work or function.”

Asked to assume equal cost-effectiveness, the patients were given eight facets of treatment and asked to rank them between 1 and 8, with 1 being the most important to them and 8 being the least.

A research team from the University of Delaware sought to see how much strength one would need, how fast they needed to walk, and how far they needed to walk to achieve a sufficient 6,000 steps in a day, and found that most knee OA patients surpassed their thresholds.